

AMENDMENTS TO THE CLAIMS

1. (Original) An inhibiting agent of the proliferation of vascular smooth muscles, comprising 14-membered ring macrolide compounds as an active ingredient.
2. (Original) An inhibiting agent according to Claim 1 wherein the vascular smooth muscles are human coronary vascular smooth muscles.
3. (Currently Amended) An inhibiting agent according to Claim 1 ~~or 2~~ wherein the 14-membered ring macrolide compounds are selected from erythromycin or its derivatives, or roxithromycin or its derivatives.
4. (Original) An inhibiting agent according to Claim 3 wherein the 14-membered ring macrolide compound is roxithromycin.
5. (Original) A potentiating agent of the expression of cyclin-dependent kinase complex (CDKIs-27), comprising 14-membered ring macrolide compounds as an active ingredient.
6. (Original) A potentiating agent according to Claim 5 wherein the 14-membered ring macrolide compounds are selected from erythromycin or its derivatives, or roxithromycin or its derivatives.
7. (Original) A potentiating agent according to Claim 6 wherein the 14-membered ring macrolide compound is roxithromycin.
8. (Original) A preventive and/or therapeutic agent for diseases caused by the proliferation or growth of vascular smooth muscles, comprising 14-membered ring macrolide compounds as an active ingredient.

9. (Original) A preventive and/or therapeutic agent according to Claim 8 wherein the disease caused by the proliferation or growth of vascular smooth muscles is arteriosclerosis or chronic vascular sclerosis concurrent with the proliferation or growth of vascular smooth muscles.

10. (Original) A preventive and/or therapeutic agent according to Claim 8 wherein the disease caused by the proliferation or growth of vascular smooth muscles is cerebrovascular stenosis, renovascular stenosis, or myocardial infarction.

11. (Currently Amended) A preventive and/or therapeutic agent according to ~~one of Claims 8-10~~claim 8 wherein the 14-membered ring macrolide compounds are selected from erythromycin or its derivatives, or roxithromycin or its derivatives.

12. (Original) A preventive and/or therapeutic agent according to Claim 11 wherein the 14-membered ring macrolide compound is roxithromycin.

13. (Original) A method for the inhibition of the proliferation or growth of vascular smooth muscles, comprising administering a therapeutically effective amount of 14-membered ring macrolide compounds.

14. (Original) A method according to Claim 13 wherein a stage from G1 phase to S phase in a cell cycle is significantly inhibited.

15. (Original) A method according to Claim 14 wherein the inhibition of the stage from G1 phase to S phase in a cell cycle is caused by inhibition of the production of phosphorylated retinoblastoma gene products.

16. (Original) A method according to Claim 14 or 15 wherein the inhibition of the stage from G1 phase to S phase in a cell cycle is caused by potentiation of the expression of cyclin-dependent kinase complex (CDKs-p27).

17. (Original) A method for the treatment of diseases caused by the proliferation or growth of vascular smooth muscles, comprising administering a therapeutically effective amount of the 14-membered ring macrolide compounds.

18. (Original) A method for the prevention of re-obstruction after the operation of obstruction in cardiac coronary artery, comprising administering a preventively effective amount of the 14-membered ring macrolide compounds.

19. (Currently Amended) A method according to one of ~~Claims 13-18~~Claims 13, 17 or 18 wherein the administration is done orally.

20. (Currently Amended) A method according to one of ~~Claims 13-19~~Claims 13, 17 or 18 wherein the 14-membered ring macrolide compounds are selected from erythromycin or its derivatives, or roxithromycin or its derivatives.

21. (Original) A method according to Claim 20 wherein the 14-membered ring macrolide compound is roxithromycin.